Oculis Holding AG (NASDAQ:OCS) Receives $42.33 Average Price Target from Analysts

Oculis Holding AG (NASDAQ:OCS) has earned an average rating of “Moderate Buy” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and eight have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $41.50.

Several analysts have issued reports on the company. Stifel Nicolaus upped their price objective on Oculis from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. JPMorgan Chase & Co. initiated coverage on Oculis in a report on Friday, December 19th. They set an “overweight” rating and a $38.00 target price for the company. Lifesci Capital started coverage on Oculis in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price target on the stock. Finally, HC Wainwright increased their target price on Oculis from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th.

Oculis Price Performance

OCS stock opened at $20.42 on Wednesday. The stock’s 50 day moving average is $20.06 and its two-hundred day moving average is $18.87. Oculis has a 52-week low of $14.00 and a 52-week high of $23.08. The company has a market capitalization of $1.07 billion, a PE ratio of -8.10 and a beta of 0.32. The company has a quick ratio of 4.47, a current ratio of 4.47 and a debt-to-equity ratio of 0.02.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10. The firm had revenue of $0.31 million for the quarter, compared to analysts’ expectations of $0.23 million. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. Analysts predict that Oculis will post -2.09 earnings per share for the current fiscal year.

Institutional Trading of Oculis

Hedge funds have recently added to or reduced their stakes in the business. Bosun Asset Management LLC bought a new position in shares of Oculis in the second quarter worth $378,000. Marshall Wace LLP bought a new stake in Oculis in the second quarter worth about $393,000. Geode Capital Management LLC boosted its position in shares of Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after purchasing an additional 6,384 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the last quarter. Finally, Woodline Partners LP raised its holdings in shares of Oculis by 65.8% in the 3rd quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after purchasing an additional 33,265 shares in the last quarter. Institutional investors own 22.30% of the company’s stock.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.